Skip to main content
BrainCited

Ginkgo biloba Cerebrovascular Health

B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。

Research suggests Ginkgo may help enhance cerebral blood flow through vasodilation. More consistent benefits are observed for vascular-related cognitive symptoms than for general cognitive decline.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dginkgo\u002Dbiloba\u0026condition\u003Dcerebrovascular\u002Dhealth'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

結論

Research suggests Ginkgo may help enhance cerebral blood flow through vasodilation. More consistent benefits are observed for vascular-related cognitive symptoms than for general cognitive decline.

Key Study Findings

Review
[Treatment of mild cognitive impairment: value of citicoline].
Dose: None vs: None Outcome: cognitive function improvement in mild cognitive impairment 効果: None None

対象集団: elderly patients with mild cognitive impairment or chronic brain diseases

Other
Antithrombotic Effect of Ginkgo Biloba Extract: A Study Based on Network Pharmacological Analysis and In …
Dose: None vs: DVT rat model vs sham control Outcome: Thrombotic wet weight, NO, cGMP, PGI2, coagulation 効果: None <0.05

対象集団: Male Sprague-Dawley rats with DVT model

In Vitro
Ginkgo biloba extract mediates HT22 cell proliferation and migration after oxygen-glucose deprivation/reoxygenation via regulating RhoA-ROCK2 …
Dose: None vs: OGD/R model vs control in HT22 cells Outcome: Cell proliferation and migration via RhoA-ROCK2 効果: None None

対象集団: HT22 mouse hippocampal neurons under OGD/R

Other 10 weeks
Ginkgo biloba Extract GBE50 ameliorates cerebrovascular dysfunction and cognitive impairment in a mouse model of …
Dose: None vs: Untreated APP/PS1 mice Outcome: Cognitive performance in behavioral tests 効果: None None

対象集団: APP/PS1 transgenic Alzheimer's disease mouse model

Review
Traditional, complementary, and integrative medicine in the management of ischemic stroke: a narrative review.
Dose: None vs: None Outcome: Ischemic stroke management outcomes 効果: None None

対象集団: Ischemic stroke patients (narrative review)

Other
Inhibition of mitochondrial oxidative stress and apoptosis in the protection of Ginkgo biloba extract 50 …
Dose: None vs: BCAS model mice without GBE50 Outcome: Cognitive impairment and white matter lesions 効果: None None

対象集団: BCAS cerebral small vessel disease mouse model

Key Statistics

12

研究数

2000

参加者数

Positive

B

グレード

Referenced Papers

Revista de neurologia None 3 件の引用
Acta pharmaceutica Sinica. … 2024 33 件の引用
The Senior care … 2021 2 件の引用
Biomedicine & pharmacotherapy … 2020 427 件の引用
The Practitioner 2010
Prescrire international 2007 2 件の引用
Annals of clinical … 2003 47 件の引用
American family physician 2003
The Medical clinics … 2002 59 件の引用
Archives of physical … 2000 408 件の引用
Current opinion in … 1998 30 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
120-240 mg/day standardized to 24% flavone glycosides and 6% terpene lactones

上限量: 600 mg/day (doses above show no additional benefit)

研究で検討された用量

用量 期間 効果 N
None -- Positive --
None -- Positive --
None -- Positive --
None 10 weeks Positive --
None -- Positive --
None -- Positive --
None -- Positive 22347
None -- Positive --

推奨摂取タイミング: With meals; may require 4-6 weeks for full effects

Safety & Side Effects

報告されている副作用

  • Headache
  • Gastrointestinal upset
  • Dizziness
  • Allergic skin reactions (rare)
  • Increased bleeding risk

既知の相互作用

  • Anticoagulants and antiplatelet drugs (increased bleeding risk)
  • Anticonvulsants (may reduce seizure threshold)
  • SSRIs (serotonin syndrome risk, rare)
  • CYP3A4 substrates (may affect drug metabolism)

耐容上限摂取量: 600 mg/day (doses above show no additional benefit)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Ginkgo biloba help with Cerebrovascular Health?
Based on 12 studies with 2,000 participants, there is moderate evidence from clinical studies that Ginkgo biloba may support Cerebrovascular Health management. Our evidence grade is B (Good Evidence).
How much Ginkgo biloba should I take for Cerebrovascular Health?
Studies have used various dosages. A commonly studied range is 120-240 mg/day standardized to 24% flavone glycosides and 6% terpene lactones. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Ginkgo biloba?
Reported side effects may include Headache, Gastrointestinal upset, Dizziness, Allergic skin reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Ginkgo biloba and Cerebrovascular Health?
We rate the evidence as Grade B (Good Evidence). This rating is based on 12 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

に関する他の成分: Cerebrovascular Health

Ginkgo biloba 他の症状・状態について

References

  1. [1] F Abad-Santos et al.. Rev Neurol. [Treatment of mild cognitive impairment: value of citicoline]. PubMed
  2. [2] Jinfa Du et al.. Proc Natl Acad Sci U S A. 2025. Identification of a central regulator of ginkgolide biosynthesis in Ginkgo biloba that integrates jasmonate and light signaling. doi:10.1073/pnas.2408891122 PubMed
  3. [3] Ting Yu et al.. Phytomedicine. 2025. Ginkgo biloba Extract GBE50 ameliorates cerebrovascular dysfunction and cognitive impairment in a mouse model of Alzheimer's disease. doi:10.1016/j.phymed.2025.156646 PubMed
  4. [4] Xing-Yuan Li et al.. J Ethnopharmacol. 2025. Inhibition of mitochondrial oxidative stress and apoptosis in the protection of Ginkgo biloba extract 50 against cognitive impairment. doi:10.1016/j.jep.2025.120059 PubMed
  5. [5] Cuicui Cheng et al.. Phytomedicine. 2025. Yindan Xinnaotong Soft Capsule improves post-ischemic stroke recovery by regulating CREB/BDNF-mediated synaptic plasticity and CREB/VEGFA-mediated angiogenesis. doi:10.1016/j.phymed.2025.157155 PubMed
  6. [6] Federico Masserini et al.. Alzheimers Dement. 2025. Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis. doi:10.1002/alz.70840 PubMed
  7. [7] S Sowmiya et al.. Front Pharmacol. 2025. Traditional, complementary, and integrative medicine in the management of ischemic stroke: a narrative review. doi:10.3389/fphar.2025.1561688 PubMed
  8. [8] H Yang et al.. Niger J Clin Pract. 2025. Antithrombotic Effect of Ginkgo Biloba Extract: A Study Based on Network Pharmacological Analysis and In vivo Experiments. doi:10.4103/njcp.njcp_770_24 PubMed
  9. [9] Dexiu Wang et al.. Metab Brain Dis. 2025. Ginkgo biloba extract mediates HT22 cell proliferation and migration after oxygen-glucose deprivation/reoxygenation via regulating RhoA-ROCK2 signalling pathway. doi:10.1007/s11011-024-01502-9 PubMed
  10. [10] Nasser M Aldekhail et al.. Altern Ther Health Med. 2025. Herbal Medicines in Autism Spectrum Disorder: Therapeutic Potential, Plant Components, and Dosage Guidelines. PubMed
  11. [11] Prabhash Nath Tripathi et al.. Degener Neurol Neuromuscul Dis. 2024. Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management Using Traditional Medicinal Plants. doi:10.2147/DNND.S452009 PubMed
  12. [12] Weile Ye et al.. Acta Pharm Sin B. 2024. [Not Available]. doi:10.1016/j.apsb.2023.09.014 PubMed
  13. [13] Liang-Yi Chen et al.. Physiol Rep. 2024. Anti-oxidative and anti-inflammatory effects of Ginkgo biloba extract (EGb761) on hindlimb skeletal muscle ischemia-reperfusion injury in rats. doi:10.14814/phy2.16050 PubMed
  14. [14] Qiuhong Zhu et al.. Pak J Pharm Sci. 2024. Clinical efficacy and mechanism of Ginkgo biloba extract in the treatment of elderly ischemic cerebrovascular disease. PubMed
  15. [15] Huan Han et al.. J Plant Physiol. 2023. Ginkgo biloba GbbZIP08 transcription factor is involved in the regulation of flavonoid biosynthesis. doi:10.1016/j.jplph.2023.154054 PubMed
  16. [16] Ting Yu et al.. Pharmaceutics. 2023. Ginkgo biloba Extract Drives Gut Flora and Microbial Metabolism Variation in a Mouse Model of Alzheimer's Disease. doi:10.3390/pharmaceutics15122746 PubMed
  17. [17] Tingchun Wu et al.. BMJ Open. 2023. Efficacy and safety of Ginkgo biloba dropping pills in the treatment of coronary heart disease with stable angina pectoris and … doi:10.1136/bmjopen-2021-055263 PubMed
  18. [18] Taizen Nakase et al.. PLoS One. 2023. Efficacy of a mixture of Ginkgo biloba, sesame, and turmeric on cognitive function in healthy adults: Study protocol for a … doi:10.1371/journal.pone.0280549 PubMed
  19. [19] Yanxia Liu et al.. J Ethnopharmacol. 2022. Leaves, seeds and exocarp of Ginkgo biloba L. (Ginkgoaceae): A Comprehensive Review of Traditional Uses, phytochemistry, pharmacology, resource utilization and … doi:10.1016/j.jep.2022.115645 PubMed
  20. [20] Min Xu et al.. J Integr Neurosci. 2022. Traditional medicine in China for ischemic stroke: bioactive components, pharmacology, and mechanisms. doi:10.31083/j.jin2101026 PubMed
  21. [21] José María García-Alberca et al.. Clin Drug Investig. 2022. Benefits of Treatment with Ginkgo Biloba Extract EGb 761 Alone or Combined with Acetylcholinesterase Inhibitors in Vascular Dementia. doi:10.1007/s40261-022-01136-8 PubMed
  22. [22] Fang Cao et al.. J Ethnopharmacol. 2022. Ginkgo biloba L. extract prevents steroid-induced necrosis of the femoral head by rescuing apoptosis and dysfunction in vascular endothelial cells … doi:10.1016/j.jep.2022.115476 PubMed
  23. [23] Li-Tao Wang et al.. Phytomedicine. 2022. Biflavonoids from Ginkgo biloba leaves as a novel anti-atherosclerotic candidate: Inhibition potency and mechanistic analysis. doi:10.1016/j.phymed.2022.154053 PubMed
  24. [24] Jie Zhang et al.. Gynecol Endocrinol. 2022. Ginkgo biloba extract 761 reduces vascular permeability of the ovary and improves the symptom of ovarian hyperstimulation syndrome in a … doi:10.1080/09513590.2022.2034147 PubMed
  25. [25] Jie Zhang et al.. Gynecol Endocrinol. 2022. Ginkgo biloba extract 761 reduces vascular permeability of the ovary and improves the symptom of ovarian hyperstimulation syndrome in a … doi:10.1080/09513590.2021.2011198 PubMed
  26. [26] Wen-Ming Yang et al.. Zhongguo Zhong Yao Za Zhi. 2022. [Expert consensus on clinical application of GBE50 Dispersible Tablets for ischemic cardiovascular and cerebrovascular diseases]. doi:10.19540/j.cnki.cjcmm.20210809.501 PubMed
  27. [27] Ju Wang et al.. Front Cell Neurosci. 2021. Traditional Chinese Medicine Monomers: Novel Strategy for Endogenous Neural Stem Cells Activation After Stroke. doi:10.3389/fncel.2021.628115 PubMed
  28. [28] Nagaendran Kandiah et al.. CNS Neurosci Ther. 2021. Strategies for the use of Ginkgo biloba extract, EGb 761® , in the treatment and management of mild cognitive impairment … doi:10.1111/cns.13536 PubMed
  29. [29] Shuang Zhao et al.. Evid Based Complement Alternat Med. 2021. The Clinical Efficacy of Ginkgo biloba Leaf Preparation on Ischemic Stroke: A Systematic Review and Meta-Analysis. doi:10.1155/2021/4265219 PubMed
  30. [30] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
  31. [31] Gang Gong et al.. Biomed Pharmacother. 2020. Isorhamnetin: A review of pharmacological effects. doi:10.1016/j.biopha.2020.110301 PubMed
  32. [32] Phui Zee Chong et al.. Am J Chin Med. 2020. Efficacy and Safety of Ginkgo biloba in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. doi:10.1142/S0192415X20500263 PubMed
  33. [33] Dan Wu et al.. Zhongguo Zhong Yao Za Zhi. 2020. [Similarities and differences between Ginkgo biloba and Panax notoginseng in treatment of ischemic cerebrovascular disease]. doi:10.19540/j.cnki.cjcmm.20200313.402 PubMed
  34. [34] Nagaendran Kandiah et al.. CNS Neurosci Ther. 2019. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba … doi:10.1111/cns.13095 PubMed
  35. [35] Egemen Savaskan et al.. Int Psychogeriatr. 2018. Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of … doi:10.1017/S1041610217001892 PubMed
  36. [36] Wei Zuo et al.. Aging Dis. 2017. Advances in the Studies of Ginkgo Biloba Leaves Extract on Aging-Related Diseases. doi:10.14336/AD.2017.0615 PubMed
  37. [37] Yinfeng Yang et al.. ACS Chem Biol. 2017. Systematic Investigation of Ginkgo Biloba Leaves for Treating Cardio-cerebrovascular Diseases in an Animal Model. doi:10.1021/acschembio.6b00762 PubMed
  38. [38] Philippa A Jackson et al.. Nutrients. 2016. DHA Supplementation Alone or in Combination with Other Nutrients Does not Modulate Cerebral Hemodynamics or Cognitive Function in Healthy Older … doi:10.3390/nu8020086 PubMed
  39. [39] Xinhua Zhou et al.. Evid Based Complement Alternat Med. 2016. Vascular Contributions to Cognitive Impairment and Treatments with Traditional Chinese Medicine. doi:10.1155/2016/9627258 PubMed
  40. [40] Ying Deng et al.. Phytother Res. 2016. Effect of Ginkgo Biloba Extract on the Pharmacokinetics and Metabolism of Clopidogrel in Rats. doi:10.1002/ptr.5691 PubMed
  41. [41] Kevin M Nash et al.. Integr Med Insights. 2015. Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders. doi:10.4137/IMI.S25054 PubMed
  42. [42] Pedro Montes et al.. CNS Neurol Disord Drug Targets. 2015. Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders. doi:10.2174/1871527314666150202151440 PubMed
  43. [43] Wen Zheng et al.. Proteomics. 2015. Improved metabolites of pharmaceutical ingredient grade Ginkgo biloba and the correlated proteomics analysis. doi:10.1002/pmic.201400258 PubMed
  44. [44] Imad A-J Thanoon et al.. Sultan Qaboos Univ Med J. 2012. Oxidative Stress and C-Reactive Protein in Patients with Cerebrovascular Accident (Ischaemic Stroke): The role of Ginkgo biloba extract. doi:10.12816/0003113 PubMed
  45. [45] Klaus P Ebmeier. Practitioner. 2010. Normal cognitive decline or dementia? PubMed
  46. [46] Oleksandr Napryeyenko et al.. J Neurol Sci. 2009. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. doi:10.1016/j.jns.2009.02.353 PubMed
  47. [47] . Prescrire Int. 2007. Ginkgo and Alzheimer's disease: little or no different from placebo. PubMed
  48. [48] Zahoor Ahmad Shah et al.. Eur Neuropsychopharmacol. 2003. Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levels. doi:10.1016/s0924-977x(03)00005-1 PubMed
  49. [49] Laura L Boles Ponto et al.. Ann Clin Psychiatry. 2003. Ginkgo biloba extract: review of CNS effects. doi:10.1023/a:1024688326023 PubMed
  50. [50] Victor S Sierpina et al.. Am Fam Physician. 2003. Ginkgo biloba. PubMed
  51. [51] Lauren T Bonner et al.. Med Clin North Am. 2002. Pharmacologic treatments of dementia. doi:10.1016/s0025-7125(02)00007-x PubMed
  52. [52] D J McKenna et al.. Altern Ther Health Med. 2001. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. PubMed
  53. [53] B J Diamond et al.. Arch Phys Med Rehabil. 2000. Ginkgo biloba extract: mechanisms and clinical indications. doi:10.1016/s0003-9993(00)90052-2 PubMed
  54. [54] S Logani et al.. Life Sci. 2000. Actions of Ginkgo Biloba related to potential utility for the treatment of conditions involving cerebral hypoxia. doi:10.1016/s0024-3205(00)00741-4 PubMed
  55. [55] V Evans. J Neurosci Nurs. 2000. Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use. doi:10.1097/01376517-200008000-00007 PubMed
  56. [56] W J Riedel et al.. Curr Opin Clin Nutr Metab Care. 1998. Nutrients, age and cognitive function. doi:10.1097/00075197-199811000-00017 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。